Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDT | P30046 | 3/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ESRRA | P11474 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70647 | 1.00 | DDT (0.57) | DDTEPHX2MEN1KMT2AGPR119 | |
| SCHEMBL83262 | 0.92 | EPHX2 (0.49) | DDTEPHX2GPR119CCR2ESRRA | |
| SCHEMBL29384868 | 0.92 | DDT (0.48) | DDTEPHX2GPR119CCR2ESRRA | |
| SCHEMBL70406 | 0.92 | DDT (0.48) | DDTEPHX2GPR119CCR2ESRRA | |
| SCHEMBL92366 | 0.92 | DDT (0.48) | DDTEPHX2GPR119CCR2ESRRA | |
| SCHEMBL83265 | 0.89 | USP30 (0.52) | DDTEPHX2GPR119ESRRA | |
| SCHEMBL69593 | 0.88 | EPHX2 (0.45) | DDTEPHX2MEN1KMT2AGPR119 | |
| SCHEMBL29382095 | 0.88 | EPHX2 (0.45) | DDTEPHX2MEN1KMT2AGPR119 | |
| SCHEMBL70091 | 0.84 | EPHX2 (0.47) | EPHX2MEN1KMT2ACCR2KCNH2 | |
| SCHEMBL29382249 | 0.84 | EPHX2 (0.47) | EPHX2MEN1KMT2ACCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12433880-B2 | Methods for the treatment of neurological disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-07 | — | — | US | disclosed |
| EP-3566055-B1 | SCD INHIBITOR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-12 | — | — | EP | disclosed |
| US-20220040167-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12433880-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | DDT 290/4885EPHX2 1185/4885MEN1 2780/4885 |
| US-20220040167-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | DDT 290/4885EPHX2 1185/4885MEN1 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.